Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shariar Cohen-gadol (NPI 1013054865)

Field	Value
Entity Type	Individual
Organization	Shariar Cohen-gadol
Address	566 Saint Charles Dr
City	Thousand Oaks
State	CA
ZIP	91360
Taxonomy	Rheumatology Physician
NPI Enumerated	January 31, 2007

Payer Source	Total Paid
Medicare	$6.2M
Medicaid	$0

Key Findings

SHARIAR COHEN-GADOL is effectively a Medicare-focused rheumatology practice with Total Medicare revenue of $6.2M and no Medicaid billing on file (none). The absence of Medicaid activity indicates the provider operates with a near–single payer exposure, concentrating commercial/Medicare negotiated rates and patient mix toward older adults and Medicare beneficiaries.

Revenue is highly concentrated in a small set of biologic injection codes: the precomputed top 3 Medicare codes account for 45.6% of this provider's total Medicare revenue. The top three contributors are J3111 ($1.1M, 17.4%), J9312 ($885.2K, 14.5%), and J0897 ($835.9K, 13.7%), which together drive nearly half of Medicare receipts and point to biologic drug administration as the primary revenue engine.

The code mix and high-volume drug codes indicate an infusion/injection–center operational model within a rheumatology scope of practice. High-revenue biologics (J3111 romosozumab, J9312 rituximab, J0897 denosumab, plus other agents such as J1602 golimumab and J0129 abatacept) and multiple infusion/chemotherapy administration codes (96413, 96401, 96415, 96375, 96372, 96365) signal that the provider routinely administers in-office parenteral biologic and antineoplastic therapies rather than relying primarily on self-administered prescriptions.

This provider is a national outlier on many high-revenue services, reflecting dominant volume for specific products and visit levels. Notable ranks include J3111 at #9 of 970 (99th percentile; extreme outlier), J9312 at #3 of 317 (99th percentile; extreme outlier), and J0897 at #26 of 10057 (100th percentile; extreme outlier), and high-ranking E/M and infusion codes such as 99214 (#276 of 479517, 100th percentile; extreme outlier) and 96413 (#51 of 7514, 99th percentile; extreme outlier).

Beyond biologics, the billing profile shows substantive procedural activity consistent with an integrated clinic offering image-guided joint procedures and musculoskeletal imaging on site. Procedures such as 20611 (935 claims, $78.5K revenue) and hyaluronan injections J7326 (285 claims, $115.1K revenue) appear alongside high national ranks for X-ray codes (73130, 73562, 73110) which suggests bundled office-based diagnostics and procedural care for rheumatology patients.

The provider’s evaluation-and-management footprint is also meaningful alongside infusion services: 99214 ($301.2K, 3K claims) and 99215 ($159.1K, 1.2K claims) are high-revenue items and both rank at extreme national percentiles, implying a significant volume of moderate- and high-complexity follow-up visits supporting ongoing biologic therapy management. The presence of 99205 (318 claims, $54.4K) further indicates notable new-patient intake at complex visit levels, consistent with a referral-oriented specialty practice.

Tenure data show the NPI was enumerated on 2007-01-31 (~19 years ago), indicating an established practice history that aligns with the scale and scope of services billed. That longevity supports the interpretation that these high-volume biologic and infusion services are part of a sustained business model rather than a recent operational change.

For payer strategy and competitive positioning, the combination of concentrated biologic revenue, high national ranks, and lack of Medicaid billing suggests the provider is a major national-level participant for select biologic administrations but does not participate in the Medicaid market. Analysts should view this profile as a high-volume, Medicare-dominant infusion and procedural rheumatology practice with specialized service lines centered on in-office biologic and infusion care.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

56 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3111	Injection, romosozumab-aqqg, 1 mg	132,510	$10	$1.1M
J9312	Injection, rituximab, 10 mg	14,050	$60	$885.1K
J0897	Injection, denosumab, 1 mg	46,440	$20	$835.9K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	169,200	$1	$676.8K
J1602	Injection, golimumab, 1 mg, for intravenous use	60,500	$10	$605K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	15,500	$30	$527K
J3262	Injection, tocilizumab, 1 mg	64,960	$10	$324.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,950	$100	$301.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	1,200	$130	$159.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,110	$120	$133.2K

Showing 1–10 of 56

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. California Distribution

Shariar Cohen-gadol — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. state median

56 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9312	2	20	4,370	$60	$382.1K
J0717	3	40	65,800	$1	$325.4K
J0129	11	80	6,610	$30	$305.3K
J3262	11	50	29,000	$1	$203.8K
J3111	2	110	14,910	$10	$171.8K
J1602	3	70	11,550	$10	$167.1K
J1745	21	70	2,350	$30	$96.5K
J0897	2	1,030	3,060	$20	$91.4K
96413	4	620	170	$120	$26.9K
99490	792	1,060	210	$50	$25.8K

Showing 1–10 of 56

Related Providers

Other providers that share a Tax Identification Number (TIN) with Shariar Cohen-gadol, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Amiel Moshfegh	CA	Vascular & Interventional Radiology Physician	$7.6M	$0
Tony Makhlouf	CA	Rheumatology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as Shariar Cohen-gadol, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Joshua Hedaya	CA	Ophthalmology Physician	$3.2M	$38.9K
Elvira Lindwall	CA	Rheumatology Physician	$2.9M	$0
Vishva Dev	CA	Interventional Cardiology Physician	$2.1M	$0
Los Robles Surgicenter, LLC	CA	Ambulatory Surgical Clinic/Center	$1.4M	$0
David Aliabadi	CA	Interventional Cardiology Physician	$1.3M	$770
Jonathan Abelson	CA	Radiation Oncology Physician	$1.2M	$0
James Lin	CA	Anesthesiology Physician	$920.3K	$0
Sean Condon	CA	MOHS-Micrographic Surgery Physician	$690.8K	$0
Trung Bui	CA	Surgery Physician	$601.6K	$71K
St Charles Surgical Center	CA	Ambulatory Surgical Clinic/Center	$636.2K	$0

Shariar Cohen-gadol — Billing Profile & Reimbursement Data

Sign up for Shariar Cohen-gadol — Billing Profile & Reimbursement Data policy alerts

Shariar Cohen-gadol — Billing Profile & Reimbursement Data

Sign up for Shariar Cohen-gadol — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References